Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals Inc.

Terns Pharmaceuticals, Inc. ( ($TERN) ) has released its Q3 earnings. Here is a breakdown of the information Terns Pharmaceuticals, Inc. presented ...

Terns Pharmaceuticals Reports Q3 2025 Results and Updates

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Terns Pharmaceuticals, with a price target of $32.0...

Mizuho Securities Sticks to Its Buy Rating for Terns Pharmaceuticals (TERN)

Barclays analyst Etzer Darout maintained a Buy rating on Terns Pharmaceuticals today and set a price target of $28.00. According to TipRanks, Darou...

Barclays Keeps Their Buy Rating on Terns Pharmaceuticals (TERN)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Terns Pharmaceuticals, with a price target of $27.00. The company...

Barclays Remains a Buy on Terns Pharmaceuticals (TERN)

An announcement from Tern plc ( ($GB:TERN) ) is now available. Tern plc announced that its total issued ordinary share capital consists of 672,713,...

Tern plc Announces Total Voting Rights Update

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Terns Pharmaceuticals, with a price target of $9.00...

Current Quarter	$-0.3	Next Quarter	$-0.31
Current Year	$-1.09	Next Year	$-1.37
QoQ Growth	-3.3%	YoY Growth	-25.7%
3Y EPS CAGR	+20.3%	Target Price	$25.11
Consensus	Buy	Upside	-4.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TERN	$26.32	+0.79%	2.49M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TERN	$26.32	+0.8%	2.49M
3
4
5
6

TERN

TERN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Terns Pharmaceuticals Inc. Data in Excel

Get Terns Pharmaceuticals Inc. Data in Excel